Encapsulated cell therapy shows positive results for macular telangiectasia
Click Here to Manage Email Alerts
The NT-501 implant demonstrated positive results in two replicative phase 3 clinical trials for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.
The investigational encapsulated cell therapy is designed to produce ciliary neurotropic factor continuously, thus changing the rate of disease progression in patients with macular telangiectasia type 2. The prespecified primary endpoint of the multicenter, randomized, sham-controlled studies was the implant’s impact on the rate of change in ellipsoid zone area loss from baseline through 24 months.
Source: Adobe Stock.
NT-501 was well tolerated by patients and demonstrated a 56.4% rate of reduction in disease progression in Protocol A (P < .0001) and a 29.2% rate of reduction in Protocol B (P = .021). These are the first phase 3 clinical results to demonstrate preservation of photoreceptors with a novel ophthalmic neuroprotectant therapy, according to the release.
“These findings are an important step towards giving hope to those currently suffering with unrelenting vision loss and who don’t have a way of stopping the progression of the disease today. We look forward to engaging with the FDA throughout the review process,” Richard Small, CEO of Neurotech, said in the release.
Read more about
Click Here to Manage Email Alerts